tradmap

DNA Ginkgo Bioworks Holdings, Inc.

$6.95 -1.14%

Updated

Healthcare · Biological Products, (No Diagnostic Substances)

Ginkgo Bioworks Holdings, Inc. (DNA) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $443 million. Shares last traded at $6.95, 60.4% below their 52-week high. Over the past year the stock is down 38.7%. Net profit margin is -260.0%, below the peer median of 5.3%. Revenue declined 25.1% year over year.

Market Cap
$443M
Shares Out
63.7M
EPS (TTM)
$-17.25
P/E Ratio
P/S Ratio
3.96
P/B Ratio
1.05
Dividend / Share
Dividend Yield
52-Week High
$17.53
52-Week Low
$5.37
Volume
24,247
Avg Vol (3m)
53,488.952

Performance

1W
-4.27%
1M
-25.91%
3M
-23.29%
6M
+1.46%
YTD
-20.11%
1Y
-38.66%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
44.26
SMA (50)
$8.17
SMA (200)
$8.30
Price vs SMA50
-14.89%
Price vs SMA200
-16.31%
ATR (14)
$0.53

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$112M
Net Income
$-291M
Gross Margin
Operating Margin
-259.9%
Net Margin
-260.0%
Return on Equity
-69.2%
Return on Assets
-29.4%
Current Ratio
4.57
Debt / Equity
1.36
Revenue Growth (YoY)
-25.1%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
FY 2025 $-5.64 2026-02-26
Q3 2025 $-4.22 2025-11-06
Q2 2025 $-2.77 2025-08-07
Q1 2025 $-1.68 2025-05-06
FY 2025 $-10.54 2026-02-26
Q3 2025 $-8.58 2025-11-06

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

DNA vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap. Updated

P/S vs peers
3.96 / 19.49 med
-80% discount
Net margin vs peers
-260.0% / 5.3% med
below median
1–14 of 14
AMGNAmgen$240.1B27.476.3023.0%+0.31%
GILDGilead Sciences$187.5B-57.876.16-10.6%+1.09%
MRNAModerna$58.8B-18.68-1.94%
RVMDRevolution Medicines, Inc.$45.2B-25.55+0.76%
BIIBBiogen$33.1B24.163.3413.8%+0.78%
NBIXNeurocrine Biosciences Inc$16.1B22.814.7720.9%+0.33%
EXELExelixis, Inc.$14.7B17.036.0235.3%+1.00%
HALOHalozyme Therapeutics, Inc.$12.6B30.397.5524.9%+1.01%
TECHBio-Techne$11.4B62.489.3515.0%+0.21%
KRYSKrystal Biotech, Inc.$11.0B45.5224.9554.8%+0.58%
APGEApogee Therapeutics, Inc.$10.2B-34.57+0.04%
KYMRKymera Therapeutics, Inc.$9.7B-32.51-1.24%
RGENRepligen Corp$9.6B230.5312.205.3%-1.87%
PCVXVaxcyte, Inc.$9.1B-8.56-0.62%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.